IntelGenx Technologies (CVE:IGX) is set to announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of C($0.03) per share for the quarter.
IntelGenx Technologies (CVE:IGX) last posted its quarterly earnings data on Friday, March 22nd. The company reported C($0.04) earnings per share for the quarter. The firm had revenue of C$0.86 million for the quarter, compared to the consensus estimate of C$0.26 million.
CVE IGX opened at C$0.72 on Wednesday. The company has a market cap of $65.47 million and a PE ratio of -5.29. The company has a debt-to-equity ratio of 79.62, a current ratio of 4.80 and a quick ratio of 4.49. IntelGenx Technologies has a 1-year low of C$0.60 and a 1-year high of C$2.36.
About IntelGenx Technologies
IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2007 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease.
Featured Story: Range Trading
Receive News & Ratings for IntelGenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.